GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences:

• H.C. Wainwright 5^th Annual NASH Investor Conference
  Tuesday, October 12, 2021
  3:30 pm Eastern Time

• H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference
  Wednesday, October 13, 2021
  4:30 pm Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™).   For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com

Source: Altimmune, Inc